Because it causes tissue damage and tissue death in the legs, feet, and toes, PAD is implicated in 150,000 lower-limb ...

Please provide your email address to receive an email when new articles are posted on . IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document ...

New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and ...

The American College of Cardiology publishes new recommendations for peripheral artery disease diagnosis and treatment among adults with diabetes.

"Our findings highlight the clinical importance of focusing on total disease burden, rather than first events, and the need for long-term preventive strategies in high-risk patients."—Michael Szarek, ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease who had an endovascular procedure, treatment with a drug-coated ...

The FDA approved the LimFlow system designed to stave off amputation for people with chronic limb-threatening ischemia (CLTI) and no treatment alternatives, device maker LimFlow SA announced Tuesday.

Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and ...

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients ...

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...